Shares of MOTIF BIO PLC/S (NASDAQ:MTFB) reached a new 52-week low on Thursday . The stock traded as low as $6.84 and last traded at $6.84, with a volume of 110 shares changing hands. The stock had previously closed at $7.10.
Several research firms recently weighed in on MTFB. HC Wainwright set a $32.00 price target on MOTIF BIO PLC/S and gave the company a “buy” rating in a report on Tuesday, August 14th. ValuEngine raised MOTIF BIO PLC/S from a “hold” rating to a “buy” rating in a research report on Tuesday, September 4th. One analyst has rated the stock with a sell rating, two have issued a hold rating and three have given a buy rating to the stock. MOTIF BIO PLC/S presently has an average rating of “Hold” and an average price target of $19.50.
The stock has a market cap of $103.94 million, a P/E ratio of -36.58 and a beta of 0.52.
TRADEMARK VIOLATION NOTICE: This story was reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this story on another site, it was illegally stolen and reposted in violation of US & international copyright and trademark legislation. The original version of this story can be read at https://www.dispatchtribunal.com/2018/12/08/motif-bio-plc-s-mtfb-reaches-new-1-year-low-at-6-84.html.
MOTIF BIO PLC/S Company Profile (NASDAQ:MTFB)
Motif Bio plc, a clinical stage biopharmaceutical company, develops and commercializes pharmaceutical formulations in the United States. The company develops novel antibiotics for the treatment of serious and life-threatening infections caused by multi-drug resistant bacteria. Its lead product candidate is iclaprim, a novel antibiotic that is in Phase III clinical trials to treat bacterial infections, such as acute bacterial skin and skin structure infections, and hospital-acquired bacterial pneumonia caused by methicillin-resistant staphylococcus aureus, as well as to treat lung infections caused by Staphylococcus aureus in patients with cystic fibrosis.
See Also: Understanding Compound Annual Growth Rate (CAGR)
Receive News & Ratings for MOTIF BIO PLC/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MOTIF BIO PLC/S and related companies with MarketBeat.com's FREE daily email newsletter.